Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells

Journal of Pathology

Volumn 222, Issue 3, 2010, Pages 271-281

  Montañez Wiscovich, Marjorie E ^a   Shelton, Melissa D ^a   Seachrist, Darcie D ^a   Lozada, Kristen L ^a   Johnson, Emhonta ^a   Miedler, John D ^b   Abdul Karim, Fadi W ^a,b   Visvader, Jane E ^c   Keri, Ruth A ^a,d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Breast cancer; Cell cycle; Centrosome; LMO4; Proliferation

Indexed keywords

PROTEIN LMO 4; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR; HOMEODOMAIN PROTEIN; LIM PROTEIN; LMO4 PROTEIN, HUMAN; MESSENGER RNA; RNA; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL PROLIFERATION; CENTROSOME; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MITOSIS SPINDLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; DEFICIENCY; FEMALE; GENETICS; METABOLISM; MITOSIS INDEX; MUTATION; PATHOLOGY; PHYSIOLOGY; SPINDLE APPARATUS; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL CYCLE; CENTROSOME; FEMALE; GENES, BRCA1; HOMEODOMAIN PROTEINS; HUMANS; LIM DOMAIN PROTEINS; MITOTIC INDEX; MUTATION; NEOPLASM PROTEINS; RECEPTORS, ESTROGEN; RNA, MESSENGER; RNA, NEOPLASM; SPINDLE APPARATUS; TRANSCRIPTION FACTORS;

EID: 77958017958     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2762     Document Type: Article

References (55)

1. Mousses S, Bubendorf L, Wagner U, et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res 2002;62:1256-1260.
2. Visvader JE, Venter D, Hahm K, et al. The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. Proc Natl Acad Sci U S A 2001;98:14452-14457.
3. Yu J, Ohuchida K, Nakata K, et al. LIM only 4 is overexpressed in late stage pancreas cancer. Mol Cancer 2008;7:93-103.
4. Sum EY, Segara D, Duscio B, et al. Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc Natl Acad Sci U S A 2005;102:7659-7664.
5. Wang N, Kudryavtseva E, Ch'en IL, et al. Expression of an engrailed-LMO4 fusion protein in mammary epithelial cells inhibits mammary gland development in mice. Oncogene 2004;23:1507-1513.
6. Wang N, Lin KK, Lu Z, et al. The LIM-only factor LMO4 regulates expression of the BMP7 gene through an HDAC2-dependent mechanism, and controls cell proliferation and apoptosis of mammary epithelial cells. Oncogene 2007;26:6431-6441.
7. Rabbitts TH. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. Genes Dev 1998;12:2651-2657.
8. Jurata LW, Gill GN. Structure and function of LIM domains. Curr Top Microbiol Immunol 1998;228:75-113.
9. Singh RR, Barnes CJ, Talukder AH, et al. Negative regulation of estrogen receptor alpha transactivation functions by LIM domain only 4 protein. Cancer Res 2005;65:10594-10601.
10. Sum EY, Peng B, Yu X, et al. The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity. J Biol Chem 2002;277:7849-7856.
11. Setogawa T, Shinozaki-Yabana S, Masuda T, et al. The tumor suppressor LKB1 induces p21 expression in collaboration with LMO4, GATA-6, and Ldb1. Biochem Biophys Res Commun 2006;343:1186-1190.
12. Lu Z, Lam KS, Wang N, et al. LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells. Oncogene 2006;25:2920-2930.
13. Montanez-Wiscovich ME, Seachrist DD, Landis MD, et al. LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression. Oncogene 2009;28:3608-3618.
14. Gomez-Smith M, Qin Z, Zhou X, et al. LIM domain only 4 protein promotes granulocyte colony-stimulating factor-induced signaling in neurons. Cell Mol Life Sci 2010;67:949-957.
15. Hinchcliffe EH, Li C, Thompson EA, et al. Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts. Science 1999;283:851-854.
16. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
17. Dulic V, Stein GH, Far DF, et al. Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol 1998;18:546-557.
18. Moynahan ME, Chiu JW, Koller BH, et al. Brca1 controls homology-directed DNA repair. Mol Cell 1999;4:511-518.
19. Wang RH, Yu H, Deng CX. A requirement for breast-cancerassociated gene 1 (BRCA1) in the spindle checkpoint. Proc Natl Acad Sci U S A 2004;101:17108- 17113.
20. Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999;3:389-395.
21. Mantel C, Braun SE, Reid S, et al. p21 (cip-1/waf-1) deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. Blood 1999;93:1390-1398.
22. Sugihara E, Kanai M, Saito S, et al. Suppression of centrosome amplification after DNA damage depends on p27 accumulation. Cancer Res 2006;66:4020-4029.
23. D'Assoro AB, Barrett SL, Folk C, et al. Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness. Breast Cancer Res Treat 2002;75:25-34.
24. Lingle WL, Barrett SL, Negron VC, et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A 2002;99:1978-1983.
25. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
26. Sum EY, O'Reilly LA, Jonas N, et al. The LIM domain protein Lmo4 is highly expressed in proliferating mouse epithelial tissues. J Histochem Cytochem 2005;53:475-486.
27. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
28. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-4671.
29. Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006;9:121-132.
30. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
31. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
32. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-524.
33. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-679.
34. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-541.
35. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triplenegative/basal-like breast carcinomas. Breast Cancer Res 2007;9: R65-R79.
36. Bhargava R, Striebel J, Beriwal S, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2009;2:444-455.
37. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-527.
38. Ko MJ, Murata K, Hwang DS, et al. Inhibition of BRCA1 in breast cell lines causes the centrosome duplication cycle to be disconnected from the cell cycle. Oncogene 2006;25:298-303.
39. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009;460:278-282.
40. Hsu LC, Doan TP, White RL. Identification of a gamma-tubulinbinding domain in BRCA1. Cancer Res 2001;61:7713-7718.
41. Doxsey SJ. Centrosomes as command centres for cellular control. Nature Cell Biol 2001;3: E105-E108.
42. Lotti LV, Ottini L, D'Amico C, et al. Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer 2002;35:193-203.
43. Novotny-Diermayr V, Lin B, Gu L, et al. Modulation of the interleukin-6 receptor subunit glycoprotein 130 complex and its signaling by LMO4 interaction. J Biol Chem 2005;280:12747-12757.
44. Schaffar G, Taniguchi J, Brodbeck T, et al. LIM-only protein 4 interacts directly with the repulsive guidance molecule A receptor Neogenin. J Neurochem 2008;107:418-431.
45. Desai KV, Xiao N, Wang W, et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A 2002;99:6967-6972.
46. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007;117:3155-3163.
47. Tokunaga E, Kimura Y, Mashino K, et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006;13:137-144.
48. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007;26:1338-1345.
49. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-2878.
50. Chakrabarti R, Jones JL, Oelschlager DK, et al. Phosphorylated LIM kinases colocalize with gamma-tubulin in centrosomes during early stages of mitosis. Cell Cycle 2007;6:2944-2952.
51. Hirota T, Kunitoku N, Sasayama T, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114:585-598.
52. Bergamaschi A, Kim YH, Wang P, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006;45:1033-1040.
53. Lu Z, Lam KS, Wang N, et al. LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells. Oncogene 2006;25:2920-2930.
54. Johnson E, Theisen CS, Johnson KR, et al. R-cadherin influences cell motility via Rho family GTPases. J Biol Chem 2004;279:31041-31049.
55. Montanez-Wiscovich ME, Seachrist DD, Landis MD, et al. LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression. Oncogene 2009;28:3608-3618.